Aditya Bardia
MD, MPH
Director, Breast Oncology Program
👥Biography 个人简介
Dr. Aditya Bardia is a pre-eminent breast oncologist and clinical trialist who led the pivotal ASCENT trial demonstrating the superiority of sacituzumab govitecan over single-agent chemotherapy in pre-treated metastatic triple-negative breast cancer, leading to its FDA approval. He has also been a key investigator in TROPiCS-02 for HR-positive HER2-negative breast cancer. His research continues to define the optimal use of TROP2-targeted ADCs.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Aditya Bardia 的研究动态
Follow Aditya Bardia's research updates
留下邮箱，当我们发布与 Aditya Bardia（UCLA David Geffen School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment